FDA approves Roche ’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

Roche today announced that the US Food and Drug Administration (FDA) has approved Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Publication date: Available online 12 June 2019Source: European Journal of RadiologyAuthor(s): G Santamaría, X Bargalló, S G Ganau, I Alonso, M Muñoz, M Mollà, PL Fernández, A PratABSTRACTOBJECTIVES: To validate the performance of multiparametric magnetic resonance (MR) imaging to assess pathologic response to neoadjuvant systemic therapy (NST) in various breast cancer subtypes considering two definitions of pCR: absence of any residual invasive cancer or DCIS (ypT0) and absence of invasive tumour cells (ypT0/is).METHODSInstitutional review board–approved retrospective study, with w...
Source: European Journal of Radiology - Category: Radiology Source Type: research
Conclusions: The use of CT information during boost field planning could reduce the risk of LR among patients undergoing BCT. Neoadjuvant and adjuvant treatments for breast cancer did not show the significant difference in respect to the outcome of LR.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter To The Editor Source Type: research
CONCLUSION: The absence of ER in breast cancer before and after NAC would be a significant prognostic factor for local recurrence and distant metastasis. Therefore, the absence of ER should be considered as important factor in determining the treatment strategy. PMID: 31204155 [PubMed - as supplied by publisher]
Source: Asian Journal of Surgery - Category: Surgery Authors: Tags: Asian J Surg Source Type: research
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer Intervention:   Radiation: Standard Trimodality Breast Imaging Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer Intervention:   Radiation: Standard Trimodality Breast Imaging Sponsor:   Masonic Cancer Center, University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Apatinib;   Drug: Paclitaxel;   Drug: Cisplatin;   Procedure: Surgery Sponsor:   RenJi Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | HER2 | Herceptin | Neoadjuvant Therapy | Pharmaceuticals